Recombinant Mouse CD96/TACTILE Protein
Beta LifeScience
SKU/CAT #: BLK-02419P-100UG
Mouse CD96 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse CD96/TACTILE Protein
Beta LifeScience
SKU/CAT #: BLK-02419P-100UG
Collections: Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse CD96/TACTILE Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Val22-Met536. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q3U0X8 |
Target Symbol | CD96/TACTILE |
Synonyms | CD96 molecule; CD96; DKFZp667E2122; TACTILE |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Val22-Met536 |
Mol. Weight | The protein has a predicted MW of 57.9 kDa. Due to glycosylation, the protein migrates to 90-130 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development. |